CP and acute kidney injury: The dosage of CP used to induce AKI in our mouse model has been selected based on its efficacy in replicating the effects of CP-induced AKI in humans, and this model has been extensively utilized in the past due to its simplicity, reproducibility, and significant clinical relevance (Zaaba et al., 2022; Al Za’abi et al., 2021a; Al Za’abi et al., 2021b; Perše and Večerić-Haler, 2018).